China Ups Penalties For Quality Violators Under Tougher Regulation
This article was originally published in The Tan Sheet
The China FDA has officially released a new regulation governing unannounced inspections for drug and device manufacturers, ranging from production to distribution to product use, with many expecting more frequent inspections and stricter enforcement. Although traditional medicine manufacturers are the main target for now, the scope of focus could be expanded.
You may also be interested in...
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Podcast: Living In China's Coronavirus Lockdown; Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.